Topical Docetaxel Enters Development for Extramammary Paget's Disease
![<![CDATA[Topical Docetaxel Enters Development for Extramammary Paget’s Disease]]>](/media/69/69dc3a2ebbea5955.1280.webp)
Palvella Therapeutics has unveiled QTORIN docetaxel, an investigational topical formulation of docetaxel intended as a localized, first-line treatment for extramammary Paget's disease (EMPD). The company announced the program on November 19, 2026. It is the third candidate to emerge from QTORIN, Palvella's proprietary platform for topical therapies aimed at rare dermatologic conditions and vascular anomalies.
The stakes are straightforward. No treatment is FDA approved for EMPD, and Palvella estimates the disease affects more than 10,000 people in the US. That's roughly a mid-sized town's worth of patients whose only real option has been the operating room.
Why target EMPD with a topical taxane?
EMPD has been managed largely with surgery. Patients often undergo repeated, disfiguring procedures involving skin grafts, and recurrence is common even after treatment. According to Palvella, the disease can also extend into deeper tissue and spread systemically.
The scientific rationale draws on clinical experience with intravenous docetaxel in metastatic EMPD. In a multicenter retrospective analysis from 12 Japanese institutions, 13 patients received monthly docetaxel as first-line chemotherapy for metastatic disease. Among the 12 patients evaluable for response:
- 58% achieved a partial response
- The disease control rate was 83%
- Median overall survival was 16.6 months
- No treatment-related deaths occurred
Palvella's bet is that this systemic activity can be redirected — turned into a localized, first-line topical option that spares patients the cumulative burden of repeated surgery. For a population that has never had an approved drug, that shift alone would change the standard of care.
What did the company say?
Wes Kaupinen, Palvella's founder and CEO, described the program as a good fit for the company's strategy. The reasoning he laid out: EMPD is rare, has no approved therapies, and has a defined regulatory path. That combination — high unmet need plus a clear route to approval — is the profile rare-disease developers look for.
What are the next steps?
Palvella has started investigational new drug (IND)-enabling work for QTORIN docetaxel. The company expects to meet with the FDA in the first half of 2027 and then plans to launch a phase 2 study.
One caveat matters here: no clinical data for the topical formulation have been reported. The Japanese retrospective data support the molecule, not the delivery route. Whether topical docetaxel can achieve meaningful local activity in EMPD lesions — and at what tolerability — is exactly what the phase 2 study will have to answer.
What does this mean for dermatology practice?
For now, nothing changes at the bedside. EMPD management remains surgical, and clinicians should treat QTORIN docetaxel as an early-stage program. But the signal is worth watching: a topical chemotherapy aimed at a skin cancer with zero approved options and a surgery-heavy treatment burden would, if it succeeds, give dermatologists a pharmacologic first-line tool they have never had. The FDA meeting in the first half of 2027 will be the next concrete milestone to follow.
Source: dermatologytimes.com
Daniel Okafor
Show full bio
Staff writer covering people, launches and day-to-day practice in Clinical dermatology, inflammatory skin disease and biologics at Derm Field.